LITS
Lite Strategy, Inc.
NASDAQ: LITS · HEALTHCARE · BIOTECHNOLOGY
$1.15
+0.00% today
Updated 2026-04-30
Market cap
$42.54M
P/E ratio
—
P/S ratio
0.31x
EPS (TTM)
$-1.82
Dividend yield
—
52W range
$1 – $8
Volume
0.3M
Lite Strategy, Inc. (LITS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $34.80M | $40.70M | $48.82M | $65.30M | $0.00 |
| Revenue growth (YoY) | — | +17.0% | +19.9% | +33.8% | -100.0% |
| Cost of revenue | $1.41M | $1.24M | $1.81M | $383000.00 | $368000.00 |
| Gross profit | $33.39M | $40.70M | $48.82M | $65.30M | $-368000.00 |
| Gross margin | 96.0% | 100.0% | 100.0% | 100.0% | — |
| R&D | $69.40M | $85.64M | $52.45M | $16.56M | $3.92M |
| SG&A | $24.41M | $30.54M | $33.13M | $23.30M | $13.53M |
| Operating income | $-60.42M | $-75.48M | $-36.76M | $14.54M | $-17.45M |
| Operating margin | -173.7% | -185.5% | -75.3% | 22.3% | — |
| EBITDA | $-41.02M | $-75.16M | $-36.38M | $25.82M | $-17.09M |
| EBITDA margin | -117.9% | -184.7% | -74.5% | 39.5% | — |
| EBIT | $-41.31M | $-75.48M | $-36.76M | $25.44M | $-17.45M |
| Interest expense | — | — | — | — | — |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-41.31M | $-54.45M | $-31.84M | $17.78M | $-15.95M |
| Net income growth (YoY) | — | -31.8% | +41.5% | +155.8% | -189.7% |
| Profit margin | -118.7% | -133.8% | -65.2% | 27.2% | — |